Celldex Therapeutics (CLDX) Current Leases (2019 - 2026)

Celldex Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Current Leases fell 2.27% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 2.27% YoY), while the FY2025 annual figure was $1.6 million, up 6.89% from the prior year.
• Current Leases was $1.5 million for Q1 2026 at Celldex Therapeutics, down from $1.6 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.8 million in Q1 2022 to a low of $1.4 million in Q3 2024.
• Historically, Current Leases has averaged $1.5 million across 5 years, with a median of $1.5 million in 2023.
• Biggest YoY gain for Current Leases was 31.34% in 2022; the steepest drop was 17.24% in 2022.
• A 5-year view of Current Leases shows it stood at $1.4 million in 2022, then increased by 11.7% to $1.6 million in 2023, then decreased by 10.04% to $1.5 million in 2024, then rose by 6.89% to $1.6 million in 2025, then declined by 5.61% to $1.5 million in 2026.
• The last three Current Leases figures came in at $1.5 million (Q1 2026), $1.6 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.